Equillium (EQ) vs Retension Pharmaceuticals (RTSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
Equillium is the larger company by market cap ($95.1 million vs $89.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | EQ | RTSN |
|---|---|---|
| Share price | $1.50 | $11.32 |
| Market cap | $95.11M | $89.22M |
| 1-day change | +6.38% | +7.50% |
| YTD return | -9.03% | — |
| 1-year return | +10.16% | — |
| 5-year return | -76.14% | — |
| EPS (TTM) | $-0.14 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $11.79 |
| 52-week low | $0.76 | $9.66 |
| Distance from 52-week high | -57.63% | -3.99% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +470.67% | — |
| Average volume | 564.39K | 789.20K |
| Shares outstanding | 63.41M | 7.88M |
| Employees | 14 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Retension Pharmaceuticals
RTSN stock →Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
EQ vs RTSN FAQ
Which is bigger, Equillium or Retension Pharmaceuticals?
Equillium (EQ) is larger, with a market capitalization of $95.11M compared with $89.22M for Retension Pharmaceuticals (RTSN).
Are Equillium and Retension Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.